Imagine a smart assistant for doctors that gathers all a patient's medical records, brain scans, and phone data into one place. It uses this information to predict the best treatment path for people with dementia, which is often tricky because they have other health issues. It also translates complex medical results into simple language that families can actually understand.
Dementia care is incredibly expensive and complicated by comorbidities, making it hard for doctors to choose the right treatment. Current diagnostic tools are not integrated, leading to inefficient care pathways and poor patient adherence.
A digital clinical decision support platform. It includes prediction models that aggregate multimodal data and a patient-facing interface for personalized prognosis information.
If you are a software provider dealing with fragmented patient data — this project developed a digital platform that automatically derives multimodal diagnostic data from imaging and medical records to improve diagnostic precision.
If you are a pharma company dealing with the rollout of disease-modifying therapies (DMT) — this project developed a system that ensures adherence to use guidelines and collects real-world data on safety and effectiveness.
If you are a clinic operator dealing with the high cost of dementia care — this project developed a clinical decision support system that optimizes care pathways to create more cost-effective care.
Based on available project data, the specific pricing or licensing costs for the platform are not disclosed; only the EU contribution of EUR 6,069,750 is mentioned.
The project aims to validate the system in a prospective clinical study, suggesting it is moving toward scale, but full industrial deployment is not yet confirmed.
Based on available project data, there is no specific mention of the IP or licensing terms for the developed models.
The platform is designed to automatically derive data from multiple sources, including imaging repositories, medical records, and mobile devices.
The project period is from 2023-05-01 to 2028-04-30.
The consortium is well-balanced for commercialization, featuring 18 partners across 11 countries. With an industry ratio of 28% (5 industrial partners) and 6 SMEs, there is a strong bridge between the 6 universities and 5 research institutes and the actual market, ensuring the digital platform is built with commercial viability in mind.
Contact Karolinska Institutet in Sweden
Contact us to explore licensing opportunities for the precision medicine platform.
